Following a myocardial infarction, full adherence to statin-containing regimens is associated with approximately 25% fewer recurrent events. The C19 measure reports a national numeric average of roughly 86% in the 2025 Star Ratings, rising to 87% in 2026, across a scored distribution spanning ten points from 1 Star below 81% to 5 Stars at 91%. Where structured outreach has been tried, the gap has proven addressable: a pharmacist-led intervention averaging seven minutes per patient raised system-wide statin prescribing from 24.7% to 56%.
AAVBC's Statin Therapy for Patients with Cardiovascular Disease Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering the dispensing and adherence rates the HEDIS SPC specification reports, ASCVD qualifying events and intensity requirements, why LDL does not determine statin eligibility, high-yield prescribing interventions, statin intolerance and rechallenge, disparity gaps affecting Black and Hispanic adults, and documentation that supports care. Grounded in current ACC, AHA, and HEDIS guidance, this guide supports consistent, individualized clinical decision-making, helping care teams sustain secondary-prevention therapy in the patients with the clearest indication, with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of C19 performance — moving far beyond quick-reference essentials. These guides provide an integrated review of measurement importance and impact, clinical integrations, technical details, challenges and barriers, strategies for team coordination and quality improvement as well as regulatory and financial considerations. The Deep-Dives combine evidence-informed clinical guidance with practical operational tools to support a deeper understanding of C19 performance and provide care teams with strategies to thrive within a value-based model.
Following a myocardial infarction, full adherence to statin-containing regimens is associated with approximately 25% fewer recurrent events. The C19 measure reports a national numeric average of roughly 86% in the 2025 Star Ratings, rising to 87% in 2026, across a scored distribution spanning ten points from 1 Star below 81% to 5 Stars at 91%. Where structured outreach has been tried, the gap has proven addressable: a pharmacist-led intervention averaging seven minutes per patient raised system-wide statin prescribing from 24.7% to 56%.
AAVBC's Statin Therapy for Patients with Cardiovascular Disease Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering the dispensing and adherence rates the HEDIS SPC specification reports, ASCVD qualifying events and intensity requirements, why LDL does not determine statin eligibility, high-yield prescribing interventions, statin intolerance and rechallenge, disparity gaps affecting Black and Hispanic adults, and documentation that supports care. Grounded in current ACC, AHA, and HEDIS guidance, this guide supports consistent, individualized clinical decision-making, helping care teams sustain secondary-prevention therapy in the patients with the clearest indication, with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of C19 performance — moving far beyond quick-reference essentials. These guides provide an integrated review of measurement importance and impact, clinical integrations, technical details, challenges and barriers, strategies for team coordination and quality improvement as well as regulatory and financial considerations. The Deep-Dives combine evidence-informed clinical guidance with practical operational tools to support a deeper understanding of C19 performance and provide care teams with strategies to thrive within a value-based model.
